Molecular Loop specializes in advanced genomic technologies, particularly through its innovative LoopCap™ technology, which integrates target capture and library preparation into a streamlined, scalable workflow. This unique probe structure enhances the efficiency of next-generation sequencing (NGS) applications, allowing researchers to conduct complex analyses with a simple and fast protocol. The technology is designed to produce high-yield, uniform libraries, which are crucial for accurate genomic studies. Additionally, LoopCap technology offers flexibility for customization, enabling the development of tailored assays to meet specific research needs across various fields, including inherited and infectious diseases.

The company’s SARS-CoV-2 Research Panel exemplifies the practical application of its technologies, providing comprehensive genome coverage through a robust workflow that minimizes the impact of strain variants. This panel employs a tiled probe design that ensures redundancy and resilience against emerging variants, making it particularly effective for monitoring and characterizing the SARS-CoV-2 virus. The four-step process, which includes reverse transcription, probe annealing, enzymatic circularization, and PCR, is designed for ease of implementation and scalability, catering to the demands of high-throughput genomic surveillance. Overall, Molecular Loop's technologies are positioned to significantly advance the capabilities of genomic research and diagnostics.

United States

Develops the LoopCap,™ a 4-step NGS workflow that removes the need for conventional library prep and generates a targeted, sequencer-ready library of molecules representing genomic regions of interest in a highly redundant manner.

Molecular Loop

Company Details